Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

6.990 -0.200 (-2.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
Analyst Expectations for Mind Medicine's Future
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
What 9 Analyst Ratings Have To Say About Mind Medicine
Via Benzinga
The Latest Analyst Ratings for Mind Medicine
Via Benzinga
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year
Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative... 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead
Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this: 
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
Psychedelic Stocks Jumped 10% Last Week
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
The 3 Best Psychedelic Stocks to Buy Now
Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside. 
Via InvestorPlace
MindMed Shareholders Vote For All Six Company Nominees At Annual Meeting, Current R&D Path Upheld
MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end. 
Via Benzinga
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
Major Psychedelic Compound-Based Research & Development Stocks: June Update
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. 
Via Benzinga
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud 
Via Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens
The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.